MEDIHALER ERGOTAMINE (ergotamine tartrate) by Teva is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. Approved for migraine. First approved in 1960.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MEDIHALER ERGOTAMINE is an inhalation aerosol formulation of ergotamine tartrate, an alpha-adrenergic blocking agent with direct vasoconstrictive effects on cranial and peripheral blood vessels. It is indicated for acute migraine treatment, particularly in patients experiencing nausea and vomiting who cannot retain oral medications. The mechanism combines ergotamine's vasoconstrictive and serotonin-antagonist properties with caffeine to enhance cranial vasoconstriction.
Product is approaching loss of exclusivity with moderate competitive pressure (30 intensity score), indicating defensive positioning and smaller support teams.
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Worked on MEDIHALER ERGOTAMINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MEDIHALER ERGOTAMINE offers limited career growth due to declining market relevance, mature lifecycle stage, and zero linked job openings. This role suits professionals seeking stable, defensive brand management experience or looking to transition from a legacy product into higher-growth Teva therapeutic areas.